Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies


This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

SparkCures ID 1132
Trial Phase Pilot Trial
Enrollment 4 Patients
Trial Sponsors
  • Rutgers Cancer Institute of New Jersey
Trial Collaborators
  • National Cancer Institute (NCI)
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patient with disease (stage) eligible per cohort
  • COHORT 1: patients undergoing high dose chemotherapy with autologous stem cell rescue and high-risk disease as defined below:
    • Diffuse large cell lymphoma or peripheral T cell lymphoma (including specified World Health Organization [WHO] subtypes) not in computed tomography (CT)-positron emission tomography (PET) complete remission at time of high dose therapy
    • Diffuse large cell lymphoma with double hit or double expressor features
    • Diffuse large cell lymphoma or peripheral T cell lymphoma (including WHO specified subtypes) refractory to standard induction therapy OR relapsing within 1 year of treatment OR in greater that second complete remission (CR)
    • Mantle cell lymphoma not in CR1
    • Multiple myeloma with ONE (or more) of the following high risk features:
      • Less than very good partial remission at time of high dose therapy
      • High Revised-International Staging System (R-ISS) (stage III 2 microglobulin >= 5.5 plus lactate dehydrogenase [LDH] > upper limit of normal [ULN] and/or del17p, t(4;14), t(14;16)) at time of diagnosis
      • Cytogenetics or fluorescent in situ hybridization (FISH) del17p
  • COHORT 2: patients with high risk disease having undergone an allogeneic hematopoietic stem cell transplant from a 10/10 human leukocyte antigen (HLA) matched donor with one of the following disease subtypes:
    • Acute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network [ELN]) at presentation
    • Diagnostic sample with either t(6;9), t(9;22), 11q23, inv 3, -5, -7, del17p, complex cytogenetics, NPMwt-flt3ITD+, OR p53 mutation (mut); patients whose samples have mutations in RUNX1 or ASXL1 are also eligible (unless the patient has favorable cytogenetics)
    • AML in CR1 with measurable minimal residual disease (MRD) by molecular (e.g., myeloid mutation profile, polymerase chain reaction [PCR] for NPM1, core-binding factor [CBF], mixed lineage leukemia [MLL]) or flow cytometry
    • AML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi)
    • Myelodysplastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation
    • Treatment-related MDS or AML
    • Acute lymphoblastic leukemia (ALL) not in CR1
    • ALL with MRD
    • Any hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant
    • Multiple myeloma
    • Non-Hodgkin lymphoma (NHL) with chemoresistant disease at time of transplant
    • Any patient undergoing allogeneic hematopoietic stem cell transplant and an anticipated rate of relapse > 80% based upon published data and for which there is consensus amongst the Hematologic Malignancies Tumor Study Group that enrollment is appropriate
  • Availability of a genetic child, genetic parent or sibling as a potential HLA haploidentical donor
  • Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures
  • DONOR: Donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched
  • DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:
    • Age >= 18 years old;
    • Normal hemogram (white blood cells [WBC] 4.0-10.0 x 10^3/mm^3; platelet count 150,000 to 440,000/mm^3 ; hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%
    • Not pregnant or lactating;
    • Not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services;
    • No uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes;
    • Meet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies)

Exclusion Criteria:

  • Non-English speaking person
  • Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < 10/10 HLA allele matched allogeneic transplant are not eligible
  • Pregnant women
  • DONOR: Non-English speaking person
  • DONOR: Pregnant women

US Trial Locations

Please visit the page for historical site information.

View Centers